Site Menu

Current Pipeline

Building a foundation for tremendous growth

At Aprecia, we are focused on enhancing our customers' experience with highly prescribed high-dose medications. The success of existing orodispersible tablets (ODTs) at low dose ranges supports a promising forecast for our first product, SPRITAM® (levetiracetam) Tablets for Oral Suspension, and for our additional product candidates that utilize ZipDose® Technology. After conducting an analysis of market performance for select ODT formulations, Aprecia is confident that the offerings in our ZipDose® product pipeline can capture considerable market share and help redefine success in this market.